The 2025/2026 influenza season saw the emergence of H3N2 subclade K, causing high infection rates and raising alarm over potential vaccine failure. However, new research suggests that H3N2 vaccine cross-reactivity remains largely preserved in adults. These findings provide much-needed clarity for clinicians advising patients on the efficacy of seasonal vaccination.

The Challenge of Antigenic Drift

Initially, ferret-based studies predicted significant antigenic drift in subclade K, which often suggests reduced vaccine protection. Consequently, public health officials feared a major mismatch between circulating strains and the annual vaccine. Despite these predictions, real-world data in adult populations showed a different pattern. Researchers measured antibody responses in human sera to compare pre- and post-vaccination levels against both vaccine-like and subclade K isolates.

Evidence of H3N2 Vaccine Cross-Reactivity

The study revealed that seasonal influenza vaccination effectively boosted antibody titres. Specifically, titres increased two-fold against the subclade K variants and three-fold against the vaccine-like strain. This indicates that the antigenic divergence between the circulating subclade K and the vaccine is limited. Furthermore, these results align with observed vaccine effectiveness in adults, suggesting that pre-existing immunity in humans plays a critical role.

Human Serology vs. Ferret Models

One of the most significant takeaways from this research is the discrepancy between ferret models and human data. While ferrets are immunologically na\u00efve, most adults have a complex history of prior infections and vaccinations. Therefore, human serologic data provides a more accurate reflection of how a population will respond to a new variant. Incorporating this data into surveillance systems can significantly improve vaccine strain selection and public health planning.

Frequently Asked Questions

Does the current flu vaccine protect against H3N2 subclade K?

Yes, research shows the seasonal vaccine induces a two-fold boost in antibody titres against subclade K, providing meaningful cross-reactivity despite minor genetic changes in the virus.

Why did ferret studies predict lower vaccine effectiveness than what was observed in humans?

Ferrets used in labs are typically na\u00efve to the flu, whereas humans have \"immune imprinting\" from previous infections and vaccines, which helps maintain broader protection against new subvariants.

Disclaimer: This content is for informational and educational purposes only and is not intended as medical advice. It does not replace professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

Wilson A et al. Seasonal vaccine-induced immunity shows preserved cross-reactivity to H3N2 subclade K in adults. EBioMedicine. 2026 Jun 12. doi: undefined. PMID: 42284681.

Centers for Disease Control and Prevention. Human Serology & Flu. Updated September 17, 2024. Accessed June 2026.

World Health Organization. Influenza (Seasonal). Fact Sheet. Accessed June 2026.